Paul Peter Tak
Paul Peter Tak is a business leader, academic, entrepreneur and clinician who has over 30 years’ experience in medicine as a prominent expert in Immunology, Internal Medicine, and Rheumatology. Paul Peter is currently the President, CEO, and Board Director of Candel Therapeutics, the Co-Founder and Board Director of Sitryx Therapeutics, and Board Director of Levicept and Citryll.
Alongside his industry career, Paul Peter has dedicated much of his life to academia and advancing our understanding in medicine. He has served as Professor of Medicine at the University of Amsterdam and holds numerous honours for his service to medicine, with a special focus on Immunology and Rheumatology.
President and CEO, @paulpetertak, MD, PhD, FMedSci, is delivering a keynote at the @britsocimm Immune Therapies Summit next week in Cambridge!
Join us to explore breakthrough approaches in immune therapeutics.
https://web-eur.cvent.com/event/ffa03d05-261d-41c7-9633-186758c1883b/summary?tm=_B4a8-iJwdB-eiyRO4nk6r-wP4If9zTYweHKsyXJqSY
#ImmuneTherapies24 #Immunology $CADL
Thank you, Jefferies, for giving me the opportunity to present today at the Jefferies Healthcare Conference in London.
#CandelTherapeutics #viral #immunotherapy #cancer $CADL
Our phase 2b #ProstateCancer trial asks: Can CAN-2409 administration stop disease progression in patients with low/intermediate risk prostate cancer who are undergoing active surveillance?
Learn more: https://www.candeltx.com/pipeline/
$CADL #ClinicalTrials
Looking forward to seeing many colleagues, business partners, and friends in London - starting tonight!
